SPRY
ARS Pharmaceuticals, Inc
4.10$
-1.0%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| – | -43.2% | +68.8% | +132.7% | +358.0% | -17.1% | +50.6% | -6.7% | |
| – | -49.3% | +150.6% | +130.2% | +357.3% | -16.6% | +44.4% | -14.8% | |
| – | -50.5% | +145.8% | +144.9% | +250.5% | -66.3% | -28.4% | -18.7% | |
| – | -50.5% | +145.8% | +144.9% | +356.8% | -16.8% | +37.5% | -22.0% | |
| – | – | – | -99.7% | +100,800.0% | -21.2% | +1,052.5% | +187.6% | |
| – | – | – | – | – | – | – | +60.6% | |
| – | – | – | +2,913.0% | -52.5% | – | – | – | |
| – | – | – | – | – | – | +1,145.5% | +88.1% | |
| – | +127.3% | +90.4% | +129.2% | -90.8% | -71.6% | +3,786.1% | +126.2% | |
| – | +248.5% | -54.2% | -0.3% | -33.5% | -56.1% | +880.3% | +67.0% | |
| – | +248.5% | -79.2% | +41.6% | -93.7% | +3.0% | -82.3% | +1,300.0% | |
| – | +353.9% | -65.3% | +46.5% | -7.1% | -54.2% | +1,200.4% | -42.0% | |
| – | – | – | -33.9% | – | – | – | – | |
| – | -130.8% | – | – | – | -15.4% | +11.3% | -55.5% | |
| – | – | – | – | – | – | – | – | |
| – | +0.0% | +4.9% | -16.8% | +38.4% | +138.3% | +7.5% | -3.7% |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.